nodes	percent_of_prediction	percent_of_DWPC	metapath
Sucralfate—FGF2—hematologic cancer	0.47	0.872	CbGaD
Sucralfate—ALB—hematologic cancer	0.0691	0.128	CbGaD
Sucralfate—EGF—ovarian follicle—hematologic cancer	0.0276	0.281	CbGeAlD
Sucralfate—FGB—hematopoietic system—hematologic cancer	0.00533	0.0542	CbGeAlD
Sucralfate—FGA—hematopoietic system—hematologic cancer	0.00456	0.0464	CbGeAlD
Sucralfate—ALB—Imatinib—hematologic cancer	0.00406	0.383	CbGbCtD
Sucralfate—FGB—gonad—hematologic cancer	0.00405	0.0412	CbGeAlD
Sucralfate—FGG—lung—hematologic cancer	0.00401	0.0408	CbGeAlD
Sucralfate—FGG—testis—hematologic cancer	0.00378	0.0385	CbGeAlD
Sucralfate—FGB—blood—hematologic cancer	0.00353	0.0359	CbGeAlD
Sucralfate—FGA—gonad—hematologic cancer	0.00347	0.0353	CbGeAlD
Sucralfate—FGB—bone marrow—hematologic cancer	0.00342	0.0347	CbGeAlD
Sucralfate—EGF—hematopoietic system—hematologic cancer	0.00333	0.0339	CbGeAlD
Sucralfate—FGB—lung—hematologic cancer	0.00309	0.0315	CbGeAlD
Sucralfate—FGA—blood—hematologic cancer	0.00302	0.0307	CbGeAlD
Sucralfate—FGA—bone marrow—hematologic cancer	0.00292	0.0297	CbGeAlD
Sucralfate—FGB—testis—hematologic cancer	0.00292	0.0297	CbGeAlD
Sucralfate—Haemolysis—Lenalidomide—hematologic cancer	0.00287	0.0258	CcSEcCtD
Sucralfate—FGG—lymph node—hematologic cancer	0.00274	0.0279	CbGeAlD
Sucralfate—FGA—Podofilox—Teniposide—hematologic cancer	0.00268	0.627	CbGdCrCtD
Sucralfate—ALB—Prednisone—hematologic cancer	0.00268	0.252	CbGbCtD
Sucralfate—FGA—lung—hematologic cancer	0.00265	0.0269	CbGeAlD
Sucralfate—ALB—Irinotecan—hematologic cancer	0.00254	0.239	CbGbCtD
Sucralfate—EGF—gonad—hematologic cancer	0.00253	0.0258	CbGeAlD
Sucralfate—FGA—testis—hematologic cancer	0.0025	0.0254	CbGeAlD
Sucralfate—EGF—blood—hematologic cancer	0.00221	0.0224	CbGeAlD
Sucralfate—Fluid overload—Idarubicin—hematologic cancer	0.00214	0.0192	CcSEcCtD
Sucralfate—Lung disorder—Pentostatin—hematologic cancer	0.00195	0.0175	CcSEcCtD
Sucralfate—EGF—lung—hematologic cancer	0.00193	0.0197	CbGeAlD
Sucralfate—Haemolysis—Cisplatin—hematologic cancer	0.00193	0.0174	CcSEcCtD
Sucralfate—Fluid overload—Busulfan—hematologic cancer	0.00193	0.0173	CcSEcCtD
Sucralfate—EGF—testis—hematologic cancer	0.00182	0.0186	CbGeAlD
Sucralfate—FGF2—lung—hematologic cancer	0.00171	0.0174	CbGeAlD
Sucralfate—Lung disorder—Busulfan—hematologic cancer	0.0017	0.0152	CcSEcCtD
Sucralfate—Lung disorder—Bexarotene—hematologic cancer	0.00161	0.0145	CcSEcCtD
Sucralfate—FGF2—testis—hematologic cancer	0.00161	0.0164	CbGeAlD
Sucralfate—FGA—Podofilox—Etoposide—hematologic cancer	0.00159	0.373	CbGdCrCtD
Sucralfate—Extravasation—Daunorubicin—hematologic cancer	0.00159	0.0143	CcSEcCtD
Sucralfate—Extravasation—Idarubicin—hematologic cancer	0.00153	0.0137	CcSEcCtD
Sucralfate—Extravasation—Teniposide—hematologic cancer	0.00148	0.0133	CcSEcCtD
Sucralfate—Venous thrombosis—Thalidomide—hematologic cancer	0.00141	0.0126	CcSEcCtD
Sucralfate—Extravasation—Busulfan—hematologic cancer	0.00138	0.0123	CcSEcCtD
Sucralfate—Fluid overload—Bortezomib—hematologic cancer	0.00135	0.0121	CcSEcCtD
Sucralfate—ALB—Methotrexate—hematologic cancer	0.00134	0.126	CbGbCtD
Sucralfate—EGF—lymph node—hematologic cancer	0.00132	0.0135	CbGeAlD
Sucralfate—Lung disorder—Bortezomib—hematologic cancer	0.00119	0.0107	CcSEcCtD
Sucralfate—Extravasation—Cladribine—hematologic cancer	0.00118	0.0106	CcSEcCtD
Sucralfate—FGF2—lymph node—hematologic cancer	0.00117	0.0119	CbGeAlD
Sucralfate—Phlebitis—Pentostatin—hematologic cancer	0.00116	0.0104	CcSEcCtD
Sucralfate—Fluid overload—Alitretinoin—hematologic cancer	0.00116	0.0104	CcSEcCtD
Sucralfate—Lung disorder—Vinorelbine—hematologic cancer	0.00116	0.0104	CcSEcCtD
Sucralfate—Venous thrombosis—Cisplatin—hematologic cancer	0.00114	0.0102	CcSEcCtD
Sucralfate—Extravasation—Vinblastine—hematologic cancer	0.00113	0.0102	CcSEcCtD
Sucralfate—Phlebitis—Idarubicin—hematologic cancer	0.00112	0.0101	CcSEcCtD
Sucralfate—Phlebitis—Teniposide—hematologic cancer	0.00109	0.00979	CcSEcCtD
Sucralfate—Extravasation—Melphalan—hematologic cancer	0.00108	0.00967	CcSEcCtD
Sucralfate—Lung disorder—Thalidomide—hematologic cancer	0.00107	0.00962	CcSEcCtD
Sucralfate—Lung disorder—Alitretinoin—hematologic cancer	0.00102	0.00915	CcSEcCtD
Sucralfate—Hyponatraemia—Pentostatin—hematologic cancer	0.00101	0.00903	CcSEcCtD
Sucralfate—Fluid overload—Cisplatin—hematologic cancer	0.000989	0.00887	CcSEcCtD
Sucralfate—Extravasation—Bortezomib—hematologic cancer	0.000964	0.00865	CcSEcCtD
Sucralfate—Phlebitis—Fludarabine—hematologic cancer	0.000959	0.00861	CcSEcCtD
Sucralfate—Lung disorder—Irinotecan—hematologic cancer	0.000957	0.00859	CcSEcCtD
Sucralfate—Extravasation—Bleomycin—hematologic cancer	0.000957	0.00858	CcSEcCtD
Sucralfate—Extravasation—Vinorelbine—hematologic cancer	0.000941	0.00844	CcSEcCtD
Sucralfate—Extravasation—Thiotepa—hematologic cancer	0.000899	0.00807	CcSEcCtD
Sucralfate—Hyponatraemia—Busulfan—hematologic cancer	0.000875	0.00785	CcSEcCtD
Sucralfate—Phlebitis—Cladribine—hematologic cancer	0.000868	0.00779	CcSEcCtD
Sucralfate—Infection—Ruxolitinib—hematologic cancer	0.000858	0.0077	CcSEcCtD
Sucralfate—Extravasation—Carmustine—hematologic cancer	0.000835	0.00749	CcSEcCtD
Sucralfate—Phlebitis—Vinblastine—hematologic cancer	0.000833	0.00747	CcSEcCtD
Sucralfate—Hyponatraemia—Bexarotene—hematologic cancer	0.000832	0.00746	CcSEcCtD
Sucralfate—Extravasation—Ifosfamide—hematologic cancer	0.000817	0.00734	CcSEcCtD
Sucralfate—Extravasation—Vincristine—hematologic cancer	0.000797	0.00715	CcSEcCtD
Sucralfate—Extravasation—Irinotecan—hematologic cancer	0.000776	0.00696	CcSEcCtD
Sucralfate—Extravasation—Mitoxantrone—hematologic cancer	0.000776	0.00696	CcSEcCtD
Sucralfate—Hyponatraemia—Nilotinib—hematologic cancer	0.000769	0.0069	CcSEcCtD
Sucralfate—Hyponatraemia—Imatinib—hematologic cancer	0.000764	0.00686	CcSEcCtD
Sucralfate—Extravasation—Gemcitabine—hematologic cancer	0.000756	0.00678	CcSEcCtD
Sucralfate—Infection—Vorinostat—hematologic cancer	0.000725	0.0065	CcSEcCtD
Sucralfate—Phlebitis—Bortezomib—hematologic cancer	0.000709	0.00636	CcSEcCtD
Sucralfate—Extravasation—Cisplatin—hematologic cancer	0.000705	0.00632	CcSEcCtD
Sucralfate—Phlebitis—Bleomycin—hematologic cancer	0.000703	0.00631	CcSEcCtD
Sucralfate—Phlebitis—Vinorelbine—hematologic cancer	0.000692	0.00621	CcSEcCtD
Sucralfate—Hyponatraemia—Melphalan—hematologic cancer	0.000685	0.00615	CcSEcCtD
Sucralfate—Body temperature increased—Ruxolitinib—hematologic cancer	0.000683	0.00612	CcSEcCtD
Sucralfate—Hyponatraemia—Lenalidomide—hematologic cancer	0.000666	0.00598	CcSEcCtD
Sucralfate—Infection—Lomustine—hematologic cancer	0.00065	0.00583	CcSEcCtD
Sucralfate—Extravasation—Etoposide—hematologic cancer	0.000646	0.00579	CcSEcCtD
Sucralfate—ALB—testis—hematologic cancer	0.000631	0.00642	CbGeAlD
Sucralfate—Infection—Mechlorethamine—hematologic cancer	0.000623	0.00559	CcSEcCtD
Sucralfate—Phlebitis—Carmustine—hematologic cancer	0.000614	0.00551	CcSEcCtD
Sucralfate—Hyponatraemia—Bortezomib—hematologic cancer	0.000613	0.0055	CcSEcCtD
Sucralfate—Phlebitis—Alitretinoin—hematologic cancer	0.000608	0.00546	CcSEcCtD
Sucralfate—Phlebitis—Ifosfamide—hematologic cancer	0.000601	0.00539	CcSEcCtD
Sucralfate—Hyponatraemia—Vinorelbine—hematologic cancer	0.000598	0.00537	CcSEcCtD
Sucralfate—Venous thrombosis—Epirubicin—hematologic cancer	0.000585	0.00525	CcSEcCtD
Sucralfate—Body temperature increased—Vorinostat—hematologic cancer	0.000577	0.00518	CcSEcCtD
Sucralfate—Phlebitis—Mitoxantrone—hematologic cancer	0.000571	0.00512	CcSEcCtD
Sucralfate—Hyponatraemia—Thalidomide—hematologic cancer	0.000553	0.00496	CcSEcCtD
Sucralfate—Venous thrombosis—Doxorubicin—hematologic cancer	0.000541	0.00486	CcSEcCtD
Sucralfate—Extravasation—Dexamethasone—hematologic cancer	0.000531	0.00477	CcSEcCtD
Sucralfate—Extravasation—Betamethasone—hematologic cancer	0.000531	0.00477	CcSEcCtD
Sucralfate—Hyponatraemia—Carmustine—hematologic cancer	0.000531	0.00476	CcSEcCtD
Sucralfate—Oedema—Nelarabine—hematologic cancer	0.000529	0.00474	CcSEcCtD
Sucralfate—Infection—Nelarabine—hematologic cancer	0.000525	0.00471	CcSEcCtD
Sucralfate—Phlebitis—Cisplatin—hematologic cancer	0.000518	0.00465	CcSEcCtD
Sucralfate—Body temperature increased—Lomustine—hematologic cancer	0.000517	0.00464	CcSEcCtD
Sucralfate—Oedema—Methoxsalen—hematologic cancer	0.000516	0.00463	CcSEcCtD
Sucralfate—Infection—Methoxsalen—hematologic cancer	0.000513	0.0046	CcSEcCtD
Sucralfate—Hyponatraemia—Vincristine—hematologic cancer	0.000507	0.00455	CcSEcCtD
Sucralfate—Oedema—Mercaptopurine—hematologic cancer	0.000502	0.0045	CcSEcCtD
Sucralfate—Oedema—Clofarabine—hematologic cancer	0.000495	0.00444	CcSEcCtD
Sucralfate—Oedema—Daunorubicin—hematologic cancer	0.000495	0.00444	CcSEcCtD
Sucralfate—Hyponatraemia—Mitoxantrone—hematologic cancer	0.000494	0.00443	CcSEcCtD
Sucralfate—Hyponatraemia—Irinotecan—hematologic cancer	0.000494	0.00443	CcSEcCtD
Sucralfate—Oedema—Anagrelide—hematologic cancer	0.000493	0.00442	CcSEcCtD
Sucralfate—Infection—Clofarabine—hematologic cancer	0.000492	0.00441	CcSEcCtD
Sucralfate—Infection—Daunorubicin—hematologic cancer	0.000492	0.00441	CcSEcCtD
Sucralfate—Infection—Anagrelide—hematologic cancer	0.000489	0.00439	CcSEcCtD
Sucralfate—Infection—Pentostatin—hematologic cancer	0.000489	0.00439	CcSEcCtD
Sucralfate—Lung disorder—Methotrexate—hematologic cancer	0.000477	0.00428	CcSEcCtD
Sucralfate—Phlebitis—Etoposide—hematologic cancer	0.000475	0.00426	CcSEcCtD
Sucralfate—Infection—Idarubicin—hematologic cancer	0.000472	0.00423	CcSEcCtD
Sucralfate—Oedema—Teniposide—hematologic cancer	0.000462	0.00415	CcSEcCtD
Sucralfate—Infection—Teniposide—hematologic cancer	0.000459	0.00412	CcSEcCtD
Sucralfate—ALB—lymph node—hematologic cancer	0.000457	0.00465	CbGeAlD
Sucralfate—Hyponatraemia—Cisplatin—hematologic cancer	0.000448	0.00402	CcSEcCtD
Sucralfate—Lung disorder—Epirubicin—hematologic cancer	0.000446	0.004	CcSEcCtD
Sucralfate—Oedema—Busulfan—hematologic cancer	0.000428	0.00384	CcSEcCtD
Sucralfate—Infection—Busulfan—hematologic cancer	0.000425	0.00382	CcSEcCtD
Sucralfate—Body temperature increased—Nelarabine—hematologic cancer	0.000418	0.00375	CcSEcCtD
Sucralfate—Oedema—Procarbazine—hematologic cancer	0.000415	0.00373	CcSEcCtD
Sucralfate—Lung disorder—Doxorubicin—hematologic cancer	0.000413	0.0037	CcSEcCtD
Sucralfate—Infection—Procarbazine—hematologic cancer	0.000413	0.0037	CcSEcCtD
Sucralfate—Body temperature increased—Methoxsalen—hematologic cancer	0.000408	0.00366	CcSEcCtD
Sucralfate—Oedema—Dasatinib—hematologic cancer	0.000407	0.00365	CcSEcCtD
Sucralfate—Oedema—Bexarotene—hematologic cancer	0.000407	0.00365	CcSEcCtD
Sucralfate—Oedema—Fludarabine—hematologic cancer	0.000406	0.00364	CcSEcCtD
Sucralfate—Infection—Dasatinib—hematologic cancer	0.000405	0.00363	CcSEcCtD
Sucralfate—Infection—Bexarotene—hematologic cancer	0.000405	0.00363	CcSEcCtD
Sucralfate—Infection—Fludarabine—hematologic cancer	0.000403	0.00362	CcSEcCtD
Sucralfate—Body temperature increased—Mercaptopurine—hematologic cancer	0.000397	0.00356	CcSEcCtD
Sucralfate—Body temperature increased—Clofarabine—hematologic cancer	0.000391	0.00351	CcSEcCtD
Sucralfate—Body temperature increased—Daunorubicin—hematologic cancer	0.000391	0.00351	CcSEcCtD
Sucralfate—Body temperature increased—Pentostatin—hematologic cancer	0.000389	0.00349	CcSEcCtD
Sucralfate—Body temperature increased—Anagrelide—hematologic cancer	0.000389	0.00349	CcSEcCtD
Sucralfate—Extravasation—Methotrexate—hematologic cancer	0.000387	0.00347	CcSEcCtD
Sucralfate—Infection—Chlorambucil—hematologic cancer	0.000382	0.00343	CcSEcCtD
Sucralfate—Oedema—Nilotinib—hematologic cancer	0.000376	0.00338	CcSEcCtD
Sucralfate—Body temperature increased—Idarubicin—hematologic cancer	0.000375	0.00337	CcSEcCtD
Sucralfate—Oedema—Imatinib—hematologic cancer	0.000374	0.00336	CcSEcCtD
Sucralfate—Infection—Nilotinib—hematologic cancer	0.000374	0.00335	CcSEcCtD
Sucralfate—Infection—Imatinib—hematologic cancer	0.000372	0.00333	CcSEcCtD
Sucralfate—Oedema—Cladribine—hematologic cancer	0.000368	0.0033	CcSEcCtD
Sucralfate—Body temperature increased—Teniposide—hematologic cancer	0.000365	0.00328	CcSEcCtD
Sucralfate—Infection—Cladribine—hematologic cancer	0.000365	0.00328	CcSEcCtD
Sucralfate—Extravasation—Epirubicin—hematologic cancer	0.000362	0.00325	CcSEcCtD
Sucralfate—Body temperature increased—Busulfan—hematologic cancer	0.000338	0.00304	CcSEcCtD
Sucralfate—Oedema—Melphalan—hematologic cancer	0.000335	0.00301	CcSEcCtD
Sucralfate—Extravasation—Doxorubicin—hematologic cancer	0.000335	0.003	CcSEcCtD
Sucralfate—Infection—Melphalan—hematologic cancer	0.000333	0.00299	CcSEcCtD
Sucralfate—Body temperature increased—Procarbazine—hematologic cancer	0.000328	0.00295	CcSEcCtD
Sucralfate—Oedema—Lenalidomide—hematologic cancer	0.000326	0.00293	CcSEcCtD
Sucralfate—Infection—Lenalidomide—hematologic cancer	0.000324	0.00291	CcSEcCtD
Sucralfate—Body temperature increased—Bexarotene—hematologic cancer	0.000322	0.00289	CcSEcCtD
Sucralfate—Body temperature increased—Dasatinib—hematologic cancer	0.000322	0.00289	CcSEcCtD
Sucralfate—Oedema—Hydroxyurea—hematologic cancer	0.000321	0.00288	CcSEcCtD
Sucralfate—Body temperature increased—Fludarabine—hematologic cancer	0.000321	0.00288	CcSEcCtD
Sucralfate—Infection—Hydroxyurea—hematologic cancer	0.000319	0.00287	CcSEcCtD
Sucralfate—Body temperature increased—Chlorambucil—hematologic cancer	0.000304	0.00273	CcSEcCtD
Sucralfate—Oedema—Bortezomib—hematologic cancer	0.0003	0.00269	CcSEcCtD
Sucralfate—Infection—Bortezomib—hematologic cancer	0.000298	0.00267	CcSEcCtD
Sucralfate—Oedema—Bleomycin—hematologic cancer	0.000298	0.00267	CcSEcCtD
Sucralfate—Body temperature increased—Nilotinib—hematologic cancer	0.000297	0.00267	CcSEcCtD
Sucralfate—Infection—Bleomycin—hematologic cancer	0.000296	0.00265	CcSEcCtD
Sucralfate—Body temperature increased—Imatinib—hematologic cancer	0.000296	0.00265	CcSEcCtD
Sucralfate—Infection—Vinorelbine—hematologic cancer	0.000291	0.00261	CcSEcCtD
Sucralfate—Body temperature increased—Cladribine—hematologic cancer	0.000291	0.00261	CcSEcCtD
Sucralfate—Infection—Thiotepa—hematologic cancer	0.000278	0.00249	CcSEcCtD
Sucralfate—Oedema—Thalidomide—hematologic cancer	0.000271	0.00243	CcSEcCtD
Sucralfate—Infection—Thalidomide—hematologic cancer	0.000269	0.00241	CcSEcCtD
Sucralfate—Phlebitis—Epirubicin—hematologic cancer	0.000266	0.00239	CcSEcCtD
Sucralfate—Oedema—Carmustine—hematologic cancer	0.00026	0.00233	CcSEcCtD
Sucralfate—Infection—Carmustine—hematologic cancer	0.000258	0.00232	CcSEcCtD
Sucralfate—Body temperature increased—Lenalidomide—hematologic cancer	0.000258	0.00231	CcSEcCtD
Sucralfate—Oedema—Alitretinoin—hematologic cancer	0.000257	0.00231	CcSEcCtD
Sucralfate—Infection—Alitretinoin—hematologic cancer	0.000256	0.0023	CcSEcCtD
Sucralfate—Oedema—Ifosfamide—hematologic cancer	0.000254	0.00228	CcSEcCtD
Sucralfate—Body temperature increased—Hydroxyurea—hematologic cancer	0.000254	0.00228	CcSEcCtD
Sucralfate—Infection—Ifosfamide—hematologic cancer	0.000253	0.00227	CcSEcCtD
Sucralfate—Oedema—Vincristine—hematologic cancer	0.000248	0.00223	CcSEcCtD
Sucralfate—Infection—Vincristine—hematologic cancer	0.000246	0.00221	CcSEcCtD
Sucralfate—Phlebitis—Doxorubicin—hematologic cancer	0.000246	0.00221	CcSEcCtD
Sucralfate—Oedema—Irinotecan—hematologic cancer	0.000242	0.00217	CcSEcCtD
Sucralfate—Oedema—Mitoxantrone—hematologic cancer	0.000242	0.00217	CcSEcCtD
Sucralfate—Infection—Irinotecan—hematologic cancer	0.00024	0.00215	CcSEcCtD
Sucralfate—Infection—Mitoxantrone—hematologic cancer	0.00024	0.00215	CcSEcCtD
Sucralfate—Body temperature increased—Bortezomib—hematologic cancer	0.000237	0.00213	CcSEcCtD
Sucralfate—Body temperature increased—Bleomycin—hematologic cancer	0.000235	0.00211	CcSEcCtD
Sucralfate—Oedema—Gemcitabine—hematologic cancer	0.000235	0.00211	CcSEcCtD
Sucralfate—Infection—Gemcitabine—hematologic cancer	0.000234	0.0021	CcSEcCtD
Sucralfate—Body temperature increased—Vinorelbine—hematologic cancer	0.000232	0.00208	CcSEcCtD
Sucralfate—Hyponatraemia—Epirubicin—hematologic cancer	0.00023	0.00206	CcSEcCtD
Sucralfate—Body temperature increased—Thiotepa—hematologic cancer	0.000221	0.00198	CcSEcCtD
Sucralfate—Oedema—Cisplatin—hematologic cancer	0.000219	0.00197	CcSEcCtD
Sucralfate—Infection—Cisplatin—hematologic cancer	0.000218	0.00196	CcSEcCtD
Sucralfate—Body temperature increased—Thalidomide—hematologic cancer	0.000214	0.00192	CcSEcCtD
Sucralfate—Hyponatraemia—Doxorubicin—hematologic cancer	0.000213	0.00191	CcSEcCtD
Sucralfate—Body temperature increased—Carmustine—hematologic cancer	0.000205	0.00184	CcSEcCtD
Sucralfate—Body temperature increased—Alitretinoin—hematologic cancer	0.000204	0.00183	CcSEcCtD
Sucralfate—Body temperature increased—Ifosfamide—hematologic cancer	0.000201	0.0018	CcSEcCtD
Sucralfate—Infection—Etoposide—hematologic cancer	0.0002	0.00179	CcSEcCtD
Sucralfate—Oedema—Prednisolone—hematologic cancer	0.000198	0.00178	CcSEcCtD
Sucralfate—Body temperature increased—Vincristine—hematologic cancer	0.000196	0.00176	CcSEcCtD
Sucralfate—Body temperature increased—Mitoxantrone—hematologic cancer	0.000191	0.00171	CcSEcCtD
Sucralfate—Body temperature increased—Irinotecan—hematologic cancer	0.000191	0.00171	CcSEcCtD
Sucralfate—Body temperature increased—Gemcitabine—hematologic cancer	0.000186	0.00167	CcSEcCtD
Sucralfate—Oedema—Triamcinolone—hematologic cancer	0.000182	0.00164	CcSEcCtD
Sucralfate—Infection—Triamcinolone—hematologic cancer	0.000181	0.00162	CcSEcCtD
Sucralfate—Body temperature increased—Cisplatin—hematologic cancer	0.000173	0.00156	CcSEcCtD
Sucralfate—Oedema—Betamethasone—hematologic cancer	0.000165	0.00148	CcSEcCtD
Sucralfate—Oedema—Dexamethasone—hematologic cancer	0.000165	0.00148	CcSEcCtD
Sucralfate—Infection—Dexamethasone—hematologic cancer	0.000164	0.00147	CcSEcCtD
Sucralfate—Infection—Betamethasone—hematologic cancer	0.000164	0.00147	CcSEcCtD
Sucralfate—Body temperature increased—Etoposide—hematologic cancer	0.000159	0.00143	CcSEcCtD
Sucralfate—Body temperature increased—Triamcinolone—hematologic cancer	0.000144	0.00129	CcSEcCtD
Sucralfate—Oedema—Prednisone—hematologic cancer	0.000144	0.00129	CcSEcCtD
Sucralfate—Infection—Prednisone—hematologic cancer	0.000143	0.00128	CcSEcCtD
Sucralfate—Body temperature increased—Dexamethasone—hematologic cancer	0.000131	0.00117	CcSEcCtD
Sucralfate—Body temperature increased—Betamethasone—hematologic cancer	0.000131	0.00117	CcSEcCtD
Sucralfate—Infection—Methotrexate—hematologic cancer	0.00012	0.00107	CcSEcCtD
Sucralfate—Body temperature increased—Prednisone—hematologic cancer	0.000114	0.00102	CcSEcCtD
Sucralfate—Oedema—Epirubicin—hematologic cancer	0.000113	0.00101	CcSEcCtD
Sucralfate—Infection—Epirubicin—hematologic cancer	0.000112	0.001	CcSEcCtD
Sucralfate—Oedema—Doxorubicin—hematologic cancer	0.000104	0.000935	CcSEcCtD
Sucralfate—Infection—Doxorubicin—hematologic cancer	0.000104	0.000929	CcSEcCtD
Sucralfate—Body temperature increased—Methotrexate—hematologic cancer	9.52e-05	0.000854	CcSEcCtD
Sucralfate—Body temperature increased—Epirubicin—hematologic cancer	8.91e-05	0.000799	CcSEcCtD
Sucralfate—Body temperature increased—Doxorubicin—hematologic cancer	8.24e-05	0.000739	CcSEcCtD
Sucralfate—FGB—Signaling Pathways—KRAS—hematologic cancer	3.39e-06	1.44e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FOXO1—hematologic cancer	3.39e-06	1.44e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PIK3R1—hematologic cancer	3.39e-06	1.44e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PDGFRB—hematologic cancer	3.38e-06	1.44e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—HRAS—hematologic cancer	3.36e-06	1.42e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—KRAS—hematologic cancer	3.35e-06	1.42e-05	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.34e-06	1.41e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IL2RA—hematologic cancer	3.34e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PDGFRA—hematologic cancer	3.33e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—KRAS—hematologic cancer	3.33e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—KRAS—hematologic cancer	3.33e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PRKCG—hematologic cancer	3.32e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—JAK1—hematologic cancer	3.32e-06	1.41e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3R1—hematologic cancer	3.32e-06	1.41e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—SRC—hematologic cancer	3.31e-06	1.4e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CA9—hematologic cancer	3.3e-06	1.4e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ACP5—hematologic cancer	3.3e-06	1.4e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—MAPK3—hematologic cancer	3.3e-06	1.4e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—JAK2—hematologic cancer	3.29e-06	1.4e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MAP2K1—hematologic cancer	3.26e-06	1.38e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOR2—hematologic cancer	3.26e-06	1.38e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3CD—hematologic cancer	3.24e-06	1.38e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—VEGFA—hematologic cancer	3.22e-06	1.37e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—JAK2—hematologic cancer	3.22e-06	1.37e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PDGFB—hematologic cancer	3.22e-06	1.36e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MDM2—hematologic cancer	3.21e-06	1.36e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—IL6—hematologic cancer	3.21e-06	1.36e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—KRAS—hematologic cancer	3.21e-06	1.36e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—MYC—hematologic cancer	3.21e-06	1.36e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—PIK3CA—hematologic cancer	3.2e-06	1.36e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—TGFB1—hematologic cancer	3.2e-06	1.36e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—BCL2—hematologic cancer	3.19e-06	1.35e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IFNG—hematologic cancer	3.16e-06	1.34e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MDM2—hematologic cancer	3.15e-06	1.33e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MTOR—hematologic cancer	3.13e-06	1.33e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PIK3CB—hematologic cancer	3.13e-06	1.33e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CDK2—hematologic cancer	3.12e-06	1.32e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—PIK3CA—hematologic cancer	3.12e-06	1.32e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—IDH1—hematologic cancer	3.11e-06	1.32e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL2RA—hematologic cancer	3.1e-06	1.31e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—PIK3CA—hematologic cancer	3.08e-06	1.3e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTO1—hematologic cancer	3.07e-06	1.3e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ABCC3—hematologic cancer	3.07e-06	1.3e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—TXN—hematologic cancer	3.07e-06	1.3e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TERT—hematologic cancer	3.07e-06	1.3e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3R1—hematologic cancer	3.06e-06	1.3e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MTOR—hematologic cancer	3.06e-06	1.3e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3CB—hematologic cancer	3.06e-06	1.3e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CD4—hematologic cancer	3.06e-06	1.3e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—PIK3CA—hematologic cancer	3.06e-06	1.3e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—PIK3CA—hematologic cancer	3.06e-06	1.3e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—MAPK3—hematologic cancer	3.05e-06	1.29e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—TP53—hematologic cancer	3.02e-06	1.28e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SPHK1—hematologic cancer	3.01e-06	1.27e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—MAPK14—hematologic cancer	3e-06	1.27e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PDGFB—hematologic cancer	2.99e-06	1.27e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—JAK2—hematologic cancer	2.98e-06	1.26e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—HRAS—hematologic cancer	2.96e-06	1.26e-05	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—AKT1—hematologic cancer	2.96e-06	1.26e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—KRAS—hematologic cancer	2.96e-06	1.26e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—TGFB1—hematologic cancer	2.96e-06	1.25e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—TP53—hematologic cancer	2.96e-06	1.25e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—TP53—hematologic cancer	2.96e-06	1.25e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—PIK3CA—hematologic cancer	2.95e-06	1.25e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CDKN1B—hematologic cancer	2.94e-06	1.24e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TSC2—hematologic cancer	2.93e-06	1.24e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MDM2—hematologic cancer	2.91e-06	1.23e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—FN1—hematologic cancer	2.9e-06	1.23e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—UGT1A1—hematologic cancer	2.89e-06	1.22e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—HRAS—hematologic cancer	2.89e-06	1.22e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CASP3—hematologic cancer	2.88e-06	1.22e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CDKN1B—hematologic cancer	2.87e-06	1.22e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IL2—hematologic cancer	2.87e-06	1.22e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—HRAS—hematologic cancer	2.85e-06	1.21e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—IL6—hematologic cancer	2.84e-06	1.2e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—MTOR—hematologic cancer	2.83e-06	1.2e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3CB—hematologic cancer	2.83e-06	1.2e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—HRAS—hematologic cancer	2.83e-06	1.2e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—HRAS—hematologic cancer	2.83e-06	1.2e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL1B—hematologic cancer	2.82e-06	1.2e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CD4—hematologic cancer	2.82e-06	1.2e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FGFR3—hematologic cancer	2.81e-06	1.19e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL2—hematologic cancer	2.81e-06	1.19e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CRABP1—hematologic cancer	2.81e-06	1.19e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SLC22A1—hematologic cancer	2.81e-06	1.19e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CCND1—hematologic cancer	2.8e-06	1.19e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—JUN—hematologic cancer	2.79e-06	1.18e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAPK14—hematologic cancer	2.79e-06	1.18e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CG—hematologic cancer	2.78e-06	1.18e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—IL6—hematologic cancer	2.76e-06	1.17e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ALOX5—hematologic cancer	2.74e-06	1.16e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—JUN—hematologic cancer	2.74e-06	1.16e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—ESR1—hematologic cancer	2.73e-06	1.16e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PTPN11—hematologic cancer	2.73e-06	1.16e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—HRAS—hematologic cancer	2.73e-06	1.16e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—PIK3CA—hematologic cancer	2.72e-06	1.15e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—CDKN1A—hematologic cancer	2.71e-06	1.15e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—IL6—hematologic cancer	2.71e-06	1.15e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—IL6—hematologic cancer	2.71e-06	1.15e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PTEN—hematologic cancer	2.7e-06	1.15e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FN1—hematologic cancer	2.7e-06	1.14e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—BAD—hematologic cancer	2.67e-06	1.13e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NFKBIA—hematologic cancer	2.67e-06	1.13e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CDKN1B—hematologic cancer	2.65e-06	1.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—CDKN1A—hematologic cancer	2.65e-06	1.12e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NUP98—hematologic cancer	2.65e-06	1.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PTEN—hematologic cancer	2.65e-06	1.12e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MAPK8—hematologic cancer	2.64e-06	1.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NOTCH1—hematologic cancer	2.64e-06	1.12e-05	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—AKT1—hematologic cancer	2.62e-06	1.11e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—IL6—hematologic cancer	2.61e-06	1.11e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MAPK8—hematologic cancer	2.59e-06	1.1e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CD80—hematologic cancer	2.59e-06	1.1e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CG—hematologic cancer	2.58e-06	1.1e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KIT—hematologic cancer	2.58e-06	1.1e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—EP300—hematologic cancer	2.58e-06	1.09e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—CREBBP—hematologic cancer	2.58e-06	1.09e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ADCY7—hematologic cancer	2.57e-06	1.09e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOA3—hematologic cancer	2.57e-06	1.09e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NUP214—hematologic cancer	2.56e-06	1.08e-05	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—AKT1—hematologic cancer	2.55e-06	1.08e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PTPN11—hematologic cancer	2.54e-06	1.08e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	2.53e-06	1.07e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—EP300—hematologic cancer	2.52e-06	1.07e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—HRAS—hematologic cancer	2.52e-06	1.07e-05	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	2.52e-06	1.07e-05	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—AKT1—hematologic cancer	2.51e-06	1.07e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—SRC—hematologic cancer	2.51e-06	1.06e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—MTR—hematologic cancer	2.5e-06	1.06e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ABCG2—hematologic cancer	2.5e-06	1.06e-05	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—AKT1—hematologic cancer	2.5e-06	1.06e-05	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—AKT1—hematologic cancer	2.5e-06	1.06e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CREB1—hematologic cancer	2.46e-06	1.04e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ENO2—hematologic cancer	2.46e-06	1.04e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—SRC—hematologic cancer	2.45e-06	1.04e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—CDKN1A—hematologic cancer	2.45e-06	1.04e-05	CbGpPWpGaD
Sucralfate—FGF2—Disease—PTEN—hematologic cancer	2.44e-06	1.04e-05	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CD—hematologic cancer	2.44e-06	1.04e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—VEGFA—hematologic cancer	2.44e-06	1.04e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—BRAF—hematologic cancer	2.43e-06	1.03e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—STAT3—hematologic cancer	2.42e-06	1.03e-05	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—NRAS—hematologic cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Sucralfate—EGF—Disease—IL6—hematologic cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Sucralfate—EGF—Immune System—AKT1—hematologic cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CCL2—hematologic cancer	2.41e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL6R—hematologic cancer	2.4e-06	1.02e-05	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CREBBP—hematologic cancer	2.4e-06	1.02e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTT1—hematologic cancer	2.38e-06	1.01e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—STAT3—hematologic cancer	2.37e-06	1e-05	CbGpPWpGaD
Sucralfate—FGF2—Immune System—NRAS—hematologic cancer	2.36e-06	1e-05	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	2.35e-06	9.94e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—EP300—hematologic cancer	2.33e-06	9.88e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—SDC1—hematologic cancer	2.33e-06	9.87e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MAPK3—hematologic cancer	2.31e-06	9.79e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3R1—hematologic cancer	2.31e-06	9.78e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAP2K1—hematologic cancer	2.29e-06	9.69e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CD—hematologic cancer	2.27e-06	9.63e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—SRC—hematologic cancer	2.27e-06	9.61e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—MAPK3—hematologic cancer	2.26e-06	9.59e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—MYC—hematologic cancer	2.25e-06	9.52e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—JAK2—hematologic cancer	2.24e-06	9.51e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TGFB1—hematologic cancer	2.24e-06	9.5e-06	CbGpPWpGaD
Sucralfate—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.23e-06	9.46e-06	CbGpPWpGaD
Sucralfate—EGF—Disease—AKT1—hematologic cancer	2.22e-06	9.43e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	2.22e-06	9.43e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—STAT3—hematologic cancer	2.18e-06	9.26e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—NRAS—hematologic cancer	2.18e-06	9.24e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3R1—hematologic cancer	2.14e-06	9.09e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CB—hematologic cancer	2.13e-06	9.03e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.1e-06	8.9e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—MAPK3—hematologic cancer	2.09e-06	8.85e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—JAK2—hematologic cancer	2.08e-06	8.84e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—KRAS—hematologic cancer	2.08e-06	8.8e-06	CbGpPWpGaD
Sucralfate—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	2.06e-06	8.72e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MDM2—hematologic cancer	2.03e-06	8.63e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—KRAS—hematologic cancer	2.03e-06	8.61e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—MYC—hematologic cancer	2.03e-06	8.61e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—TGFB1—hematologic cancer	2.02e-06	8.59e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MTOR—hematologic cancer	1.98e-06	8.39e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CB—hematologic cancer	1.98e-06	8.39e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CD44—hematologic cancer	1.98e-06	8.39e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NQO1—hematologic cancer	1.98e-06	8.39e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—IL2—hematologic cancer	1.96e-06	8.29e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.94e-06	8.22e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—PIK3CA—hematologic cancer	1.91e-06	8.09e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—KRAS—hematologic cancer	1.88e-06	7.95e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CYCS—hematologic cancer	1.87e-06	7.94e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—PIK3CA—hematologic cancer	1.87e-06	7.91e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HSP90AA1—hematologic cancer	1.86e-06	7.89e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CDKN1B—hematologic cancer	1.86e-06	7.88e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—TP53—hematologic cancer	1.84e-06	7.82e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CASP3—hematologic cancer	1.82e-06	7.72e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL2—hematologic cancer	1.82e-06	7.71e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CCND1—hematologic cancer	1.77e-06	7.51e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—JUN—hematologic cancer	1.77e-06	7.5e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—HRAS—hematologic cancer	1.76e-06	7.48e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—EP300—hematologic cancer	1.75e-06	7.44e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—HRAS—hematologic cancer	1.73e-06	7.32e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—PIK3CA—hematologic cancer	1.72e-06	7.31e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—CDKN1A—hematologic cancer	1.71e-06	7.27e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PTEN—hematologic cancer	1.71e-06	7.25e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—SRC—hematologic cancer	1.71e-06	7.23e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—IL6—hematologic cancer	1.69e-06	7.16e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.67e-06	7.1e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAPK8—hematologic cancer	1.67e-06	7.1e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—VEGFA—hematologic cancer	1.66e-06	7.05e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—IL6—hematologic cancer	1.65e-06	7.01e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTP1—hematologic cancer	1.65e-06	7e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—NRAS—hematologic cancer	1.64e-06	6.96e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—EP300—hematologic cancer	1.63e-06	6.92e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.6e-06	6.77e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—HRAS—hematologic cancer	1.59e-06	6.76e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—SRC—hematologic cancer	1.59e-06	6.73e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—MAPK3—hematologic cancer	1.57e-06	6.67e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—ABCB1—hematologic cancer	1.56e-06	6.63e-06	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—AKT1—hematologic cancer	1.56e-06	6.61e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—VEGFA—hematologic cancer	1.54e-06	6.55e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—STAT3—hematologic cancer	1.53e-06	6.49e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—NRAS—hematologic cancer	1.53e-06	6.47e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—IL6—hematologic cancer	1.53e-06	6.47e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—TGFB1—hematologic cancer	1.53e-06	6.47e-06	CbGpPWpGaD
Sucralfate—FGF2—Immune System—AKT1—hematologic cancer	1.52e-06	6.47e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—GSTM1—hematologic cancer	1.52e-06	6.43e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—NCOR1—hematologic cancer	1.52e-06	6.43e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MAPK3—hematologic cancer	1.46e-06	6.2e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—MYC—hematologic cancer	1.42e-06	6.03e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TGFB1—hematologic cancer	1.42e-06	6.01e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—KRAS—hematologic cancer	1.41e-06	5.99e-06	CbGpPWpGaD
Sucralfate—FGF2—Disease—AKT1—hematologic cancer	1.41e-06	5.97e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—MTHFR—hematologic cancer	1.34e-06	5.69e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KRAS—hematologic cancer	1.31e-06	5.57e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—PIK3CA—hematologic cancer	1.3e-06	5.5e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—TP53—hematologic cancer	1.26e-06	5.32e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—PIK3CA—hematologic cancer	1.21e-06	5.12e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—HRAS—hematologic cancer	1.2e-06	5.09e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.18e-06	5.01e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—TP53—hematologic cancer	1.17e-06	4.95e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CG—hematologic cancer	1.13e-06	4.78e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—HRAS—hematologic cancer	1.12e-06	4.73e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—IL6—hematologic cancer	1.07e-06	4.53e-06	CbGpPWpGaD
Sucralfate—ALB—Hemostasis—AKT1—hematologic cancer	1.06e-06	4.5e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—CREBBP—hematologic cancer	1.04e-06	4.43e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CD—hematologic cancer	9.9e-07	4.2e-06	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—AKT1—hematologic cancer	9.86e-07	4.18e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3R1—hematologic cancer	9.35e-07	3.97e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CB—hematologic cancer	8.63e-07	3.66e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PTEN—hematologic cancer	7.46e-07	3.16e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—EP300—hematologic cancer	7.11e-07	3.02e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—PIK3CA—hematologic cancer	5.26e-07	2.23e-06	CbGpPWpGaD
Sucralfate—ALB—Metabolism—AKT1—hematologic cancer	4.3e-07	1.82e-06	CbGpPWpGaD
